🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Excellent talk on biomarker space for prostate cancer- current state and future directions ⁦Daniel E Spratt⁩ ⁦Chirag Shah⁩ ⁦AHN⁩

IMNI reduced DM and BCM leading to better OS in node-positive breast cancer patients treated with newer systemic and 3D radiation therapies. ⁦Chirag Shah⁩ ⁦Erin Gillespie, MD MPH⁩ ⁦Icro Meattini⁩ ⁦ARRO⁩ ⁦ACROresident⁩ thelancet.com/journals/lanep…

Largest dataset showing prognostic significance of MLH1- hyper methylation for endometrial cancer ⁦DrKamrava⁩ ⁦ASTRO⁩ ⁦Ann Klopp⁩ ⁦Emma Fields, MD⁩ effort lead by Lara Hathout and her team pubmed.ncbi.nlm.nih.gov/40379143/

Again brings up issue of control arm of esopec not having this option Prajnan Das, MD, MS, MPH Dr. Nina Niu Sanford Krishan Jethwa

Confirms and establishes new SOC. First one comparing SRS to HAWBRT showing less symptom burden and better functional outcome with SRS Andrew Keller ARRO ACROresident

We're hiring! Looking for a Director of MR Guided Radiation Therapy to join a growing team with a focus on trial development, programmatic growth, teaching. Apply here or feel free to reach out to me privately: careers.highmarkhealth.org/cancer-institu…

One error,double classifier endometrial can occur in 5 to 10% are sometimes offered treatment based on worse molecular while data suggests reverse MMRd–p53abn EC behaves like MMRd and POLEmut–p53abn EC behaves as POLEmut ⁦⁩ ⁦⁩ ⁦ARRO⁩ pmc.ncbi.nlm.nih.gov/articles/PMC70…

Final Update CATNON ASCO 2025 · Median F/U 11 yrs · NO sig benefit concurrent TMZ · Sig benefit (HR 0.54) Adjuvant TMZ in IDHm (median OS 12.5 years) · NO benefit w/TMZ for IDHwt

‼️ TAUTEM Phase 3 RCT T2-3bN0M0 rectal cancer -> chemoradiation and transanal excision vs TME DFS in both groups was 88.9%! Win for organ preservation and patients! jamanetwork.com/journals/jamas…

NACRT better than NACT for resection and survival for locally advanced GB cancer. Nice work Tata Memorial Hospital

This study reports on incredible results with adjuvant cemiplimab in high-risk cutaneous squamous cell carcinoma. nejm.org/doi/full/10.10…

Finally one positive data on breast cancer for oligoprogression. Focused only on HR positive breast cancer unlike previous studies with goal to continue same systemic treatment #bcsm

Adaptive brachy - why and how ? Winship Grand Rounds: April 23, 2025 - Sushil Beriwal, MD youtu.be/WH0CZ0IBne8?si… via YouTube American Brachy DrKamrava Andrew Keller ARRO Emma Fields, MD Scott Glaser Reshma Jagsi Jill Remick

Great work with 1st author Parisa Shams and led by AHN radonc Colin Champ, M.D. in JAMA Network Open : Resistance Training and Lymphedema in Breast Cancer Survivors | Nutrition, Obesity, Exercise | JAMA Network Open | JAMA Network #bcsm Sushil David L. Bartlett, MD

Our Study showing safety and improvement in lymphedema with intense resistance/strength training

With recent NEJM publications, increased interest in exercise in oncology . ⁦Colin Champ, M.D.⁩ leading one of its kind structured program in this sphere ⁦AHN⁩ #bcsm ⁦Chirag Shah⁩ jamanetwork.com/journals/jaman…

More to learn from molecular based treatment for endometrial cancer DrKamrava

Multi institution largest series for definitive chemo RT for cancel of vulva lead by Anupam Rishi from Moffet ⁦Scott Glaser⁩ ⁦DrKamrava⁩ ⁦Emma Fields, MD⁩ ⁦Ann Klopp⁩ ⁦ARRO⁩ pubmed.ncbi.nlm.nih.gov/40513383/

Practical guide for selection of hybrid applicator for cervical cancer American Brachy DrKamrava Andrew Keller Andrew Farach, MD medicalaffairs.varian.com/image/Selectio…

Fun interactive case based session on hybrid cervical brachytherapy #abs25 Andrew Farach, MD Neil K. Taunk Yasmin Hassan Andrew Keller Pranshu Mohindra DrKamrava